These private Medicare plans denied specialized care at highest rates

Federal oversight found major Medicare Advantage insurers denied more than half of requests for long-term care or rehabilitation, with CVS Health/Aetna rejecting 80% of long-term care requests and Humana and UnitedHealth denying more than 70%. UnitedHealth denied 66% of rehabilitation requests, while appeals overturned 36% of long-term care hospital denials and 43% of rehab denials, suggesting some medically necessary care was initially withheld. The findings increase scrutiny on prior authorization practices and could pressure Medicare Advantage operators, especially for-profit plans.

Analysis

This is not just an optics problem; it is a margin-duration problem for the MA trio. The second-order risk is that elevated denials accelerate beneficiary dissatisfaction exactly where churn economics are already fragile, forcing higher retention spend, richer supplemental benefits, or softer bid discipline over the next 2-4 renewal cycles. Even if regulators do nothing immediately, the companies are now being pulled into a less flexible operating regime where each incremental prior-auth cut saves near-term medical expense but increases the probability of longer-term mix deterioration and reputational drag.

The more important market implication is that the burden may migrate to downstream providers and home-based care capacity, not disappear. If more post-acute demand is forced toward lower-cost settings, you get a pressure valve for short-term medical cost ratios but rising strain on skilled nursing and home-health networks, which can create localized capacity bottlenecks and wage inflation. That dynamic can eventually boomerang back into higher readmission rates and worse quality metrics, which are the kind of slow-moving variables that can impair MA star-rating economics with a lag.

Consensus may be overstating the immediacy of headline regulatory risk and understating the durability of earnings power. The likely near-term outcome is not an earnings reset but a gradual rise in administrative friction, appeal costs, and compliance overhead, with the biggest P&L effect showing up in 2H25 and 2026 bid/pricing behavior. The contrarian angle is that a broad selloff in these names can become a buy-the-dip event if investors conclude the issue is more about process redesign than outright benefit compression; the key is whether appeals rates and CMS scrutiny continue trending up over the next few quarters.

Key Decisions for Investors

• Short CVS vs. long XLV for 1-3 months: CVS has the most exposed optics/regulatory overhang and weaker flexibility to absorb process-cost inflation; use the hedge to isolate idiosyncratic risk while keeping sector exposure neutral.
• Reduce HUM/UNH position sizing into strength over the next 2-4 weeks; the trade is less about immediate EPS risk and more about multiple compression if CMS signals a broader review of MA utilization management.
• Buy 3-6 month puts or put spreads on UNH and CVS around the next regulatory/newsflow window; the best payoff is a negative catalyst extension rather than an outright one-day gap move.
• Long post-acute enablers selectively: consider a basket long in home-health or rehab-capacity names versus short MA insurers if evidence builds that denials are pushing care downstream and worsening provider scarcity pricing.
• If the group sells off hard on headline risk, cover shorts partially into the drawdown and wait for confirmation from appeal/denial trend data; the asymmetry improves only if CMS turns rhetoric into enforcement.